Arrowstreet Capital
VIVO

Arrowstreet Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Arrowstreet Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-469,032
Closed -$8.77M – 2638
2020
Q4 		$8.77M Sell
469,032
-112,664
-19% -$2.1M 0.01% 932
2020
Q3 		$9.88M Buy
581,696
+17,600
+3% +$342K 0.02% 846
2020
Q2 		$13.1M Buy
564,096
+401,096
+246% +$5.81M 0.02% 669
2020
Q1 		$1.37M Sell
163,000
-98,772
-38% -$832K ﹤0.01% 1203
2019
Q4 		$2.56M Buy
261,772
+39,150
+18% +$368K 0.01% 1059
2019
Q3 		$2.11M Buy
222,622
+31,324
+16% +$330K ﹤0.01% 972
2019
Q2 		$2.27M Sell
191,298
-21,796
-10% -$263K 0.01% 873
2019
Q1 		$3.75M Sell
213,094
-77,765
-27% -$1.29M 0.01% 889
2018
Q4 		$5.05M Buy
290,859
+114,754
+65% +$1.96M 0.01% 579
2018
Q3 		$2.62M Buy
176,105
+106,140
+152% +$1.65M 0.01% 646
2018
Q2 		$1.11M Buy
69,965
+7,380
+12% +$110K ﹤0.01% 781
2018
Q1 		$889K Sell
62,585
-14,218
-19% -$210K ﹤0.01% 891
2017
Q4 		$1.07M Buy
+76,803
New +$1.12M ﹤0.01% 946
2016
Q4 		– Sell
-104,650
Closed -$2.02M – 2659
2016
Q3 		$2.02M Sell
104,650
-7,959
-7% -$156K 0.01% 927
2016
Q2 		$2.2M Buy
112,609
+36,700
+48% +$720K 0.01% 812
2016
Q1 		$1.56M Sell
75,909
-44,000
-37% -$867K 0.01% 869
2015
Q4 		$2.46M Buy
119,909
+17,209
+17% +$330K 0.01% 745
2015
Q3 		$1.76M Buy
+102,700
New +$1.88M 0.01% 779
2014
Q4 		– Sell
-11,625
Closed -$206K – 1365
2014
Q3 		$206K Buy
+11,625
New +$228K ﹤0.01% 936
2013
Q4 		– Sell
-13,956
Closed -$330K – 1325
2013
Q3 		$330K Buy
+13,956
New +$326K ﹤0.01% 843

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Arrowstreet Capital's VIVO Position: Q1 2021 in Review

Arrowstreet Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 469,032 shares — an estimated $8.77M sold.

Arrowstreet Capital first reported a position in VIVO in Q3 2013 and held it in 20 quarters. The position peaked at $13.1M in Q2 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

  • Arrowstreet Capital reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 469,032 Meridian Bioscience Inc shares in Q1 2021, an estimated $8.77M.
  • Arrowstreet Capital first reported a position in Meridian Bioscience Inc in Q3 2013 and held it in 20 quarters.
  • Arrowstreet Capital's Meridian Bioscience Inc position peaked at $13.1M in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.